Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocation details rather than corporate financial performance.
Material Changes
On December 31, 2010, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of October 1, 2010, to December 31, 2010. The allocation price was set at £12.55 per Ordinary share and $39.18 per ADS. These allocations were formally notified to the Company and the Directors on January 4, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each Non-Executive Director listed in the filing.
- Confirm the allocation price of £12.55 per Ordinary share and $39.18 per ADS against market prices on December 31, 2010.
- Review the full share allocation arrangements for Non-Executive Directors to understand vesting terms and conditions not detailed in this summary.